早期乳腺癌辅助化疗与靶向治疗选择:ASCO指南更新
ASCO专家组通过靶向系统性文献综述更新早期乳腺癌辅助化疗和靶向治疗推荐。基于KATHERINE试验,对新辅助化疗和HER2靶向治疗后仍有浸润性残留病灶的HER2阳性乳腺癌患者,推荐14周期辅助T-DM1;T-DM1组无浸润性疾病生存显著优于曲妥珠单抗组(HR 0.50)。
要点
- HER2阳性乳腺癌新辅助化疗及靶向治疗后手术有浸润性残留病灶,应给予14周期辅助T-DM1。
- KATHERINE试验中T-DM1组无浸润性疾病生存显著优于曲妥珠单抗组(HR 0.50)。
- T-DM1组3级及以上不良事件发生率25.7%,高于曲妥珠单抗组的15.4%。
核心结论
- 对HER2阳性早期乳腺癌新辅助治疗后仍有浸润性残留病灶者,辅助T-DM1较曲妥珠单抗显著改善无浸润性疾病生存。
研究设计与样本
- ASCO专家组采用信号导向的靶向系统性文献综述,纳入III期开放标签KATHERINE试验。
主要发现
- T-DM1组远处复发风险低于曲妥珠单抗组(HR 0.60;95%CI 0.45-0.79)。
- T-DM1组3级及以上不良事件190例(25.7%),曲妥珠单抗组111例(15.4%)。
关键数值与推荐
- HER2阳性乳腺癌患者经标准术前化疗和HER2靶向治疗后手术有病理浸润性残留病灶,应接受14周期辅助T-DM1,除非疾病复发或毒性不可管理。
- 临床医生可选用任何可用且已批准的曲妥珠单抗制剂,包括曲妥珠单抗、曲妥珠单抗透明质酸酶-oysk及可用生物类似药。
临床怎么用
- 对HER2阳性早期乳腺癌新辅助治疗后未达病理完全缓解且有浸润性残留病灶者,辅助治疗应优先选择T-DM1。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this work is to update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. METHODS: An Expert Panel conducted a targeted systematic literature review guided by a signals approach to identify new, potentially practice-changing data that might translate into revised guideline recommendations. RESULTS: The Expert Panel reviewed abstracts from the literature review and identified one article for inclusion that reported results of the phase III, open-label KATHERINE trial. In the KATHERINE trial, patients with stage I to III human epidermal growth factor receptor 2 (HER2)-positive breast cancer with residual invasive disease in the breast or axilla after completing neoadjuvant chemotherapy and HER2-targeted therapy were allocated to adjuvant trastuzumab emtansine (T-DM1; n = 743) or to trastuzumab (n = 743). Invasive disease-free survival was significantly higher in the T-DM1 group than in the trastuzumab arm (hazard ratio, 0.50; 95% CI, 0.39 to 0.64; P < .001), and risk of distant recurrence was lower in patients who received T-DM1 than in patients who received trastuzumab (hazard ratio, 0.60; 95% CI, 0.45 to 0.79). Grade 3 or higher adverse events occurred in 190 patients (25.7%) who received T-DM1 and in 111 patients (15.4%) who received trastuzumab. RECOMMENDATIONS: Patients with HER2-positive breast cancer with pathologic invasive residual disease at surgery after standard preoperative chemotherapy and HER2-targeted therapy should be offered 14 cycles of adjuvant T-DM1, unless there is disease recurrence or unmanageable toxicity. Clinicians may offer any of the available and approved formulations of trastuzumab, including trastuzumab, trastuzumab and hyaluronidase-oysk, and available biosimilars.Additional information can be found at www.asco.org/breast-cancer-guidelines.
引用
- Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2020. PMID: 33079579. doi:10.1200/JCO.20.02510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。